Close

Guggenheim Reiterates Buy as Medicines Co. (MDCO) Prepares Phase 2 Data

August 15, 2016 7:26 AM EDT Send to a Friend
Guggenheim reiterated a Buy rating and $55.00 price target on The Medicines Company (NASDAQ: MDCO) as the company prepares to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login